Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.
Peptide-based strategies just took a big step forward in managing surface-initiated thrombogenesis. Researchers at Stony Brook University tested a fibronectin-derived peptide, P12, for its ability to stop blood clots from forming on artificial surfaces and inflamed blood vessels — a stubborn problem in medical device research and viral infection settings.
J Thromb Haemost
by Hansen A, Essuman B, Kementzidis G et al.
“Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis. Hansen A(1), Essuman B(2), Kementzidis G(3), Tripti NJ(3), Lin F(4), Chernyshenko V(5), Clark RAF(6), Deng Y(3), Rafailovich M(7), Galanakis DK(8). Author information: (1)Department of Materials Science and Chemical Engineering, Stony Brook University, Stony Brook, NY 11794. Electronic address: adam.hansen@stonybrook.edu. (2)Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794. (3)Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY 11794. (4)Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794. (5)Department of Protein Structure and Function, Palladin Institute of Biochemistry of NAS of Ukraine, Kyiv, Ukraine 03680. (6)Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794; Department of Dermatology, Stony Brook University, Stony Brook, NY 11794. (7)Department of Materials Science and Chemical Engineering, Stony Brook University, Stony Brook, NY 11794. (8)Department of Pathology, Stony Brook University, Stony Brook, NY 11794. BACKGROUND: Surface-induced fibrinogen misfolding drives thrombogenesis at hydrophobic material interfaces, as demonstrated in our prior mechanistic model. Extending this concept to pathophysiological settings, viral infection creates a clinically relevant prothrombotic environment by promoting lipid droplet release and elevating circulating fibrinogen levels, generating vascular interfaces that favor aberrant fibrin assembly. Targeted peptide inhibitors may provide a selective strategy to interrupt this surface-mediated process. P12, a fibronectin-derived peptide previously shown to attenuate burn progression, is a promising candidate for modulating surface-driven thrombogenesis. OBJECTIVES: To evaluate whether P12 disrupts surface-initiated thrombogenesis on biomaterial surfaces and prothrombotic endothelium and to define its mechanism of action. METHODS: P12-fibrin(ogen) interactions were assessed by immunofluorescence and supported by molecular dynamics simulations. Effects on fibrin(ogen) assembly, from molecular interactions to macroscopic clot formation, were analyzed using complementary multi-scale microscopy techniques. RESULTS: P12 selectively bound fibrin(ogen) within the αC-domain, specifically the N-terminal subdomain (Aα392-503), with preferential interaction spanning residues Aα476-496. Binding inhibited intermolecular interactions among surface-bound fibrin(ogen) and disrupted protofibril formation, thereby limiting fibrin assembly. P12 also bound soluble fibrin, reducing both its surface adsorption and ability to aggregate into fibers. Consistent with these effects, platelet accumulation was markedly reduced and thrombogenesis suppressed. Importantly, these inhibitory effects were preserved in a pathological context involving viral infection. CONCLUSION: A targeted peptide can effectively inhibit surface-initiated thrombogenesis without directly impairing physiological clotting mechanisms. These findings support the translational potential of P12 for treating pathological thrombosis and inform the rational design of antithrombotic surfaces and therapeutics. Copyright © 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.”
Here’s what matters: P12 didn’t just slow down fibrin assembly, it disrupted the whole process at the molecular level. This peptide bound specifically to the αC-domain of fibrinogen, targeting a narrow stretch of amino acids (Aα476-496). The result? Fibrin molecules couldn’t stick together properly, protofibril formation was blocked, and full-blown clots struggled to form. Even soluble fibrin in the bloodstream had trouble aggregating once P12 was in the mix.
The real kicker: This effect held up even under pathological conditions, including those mimicking viral infections where clotting risk spikes. Platelet clumping dropped, and thrombosis got shut down — all without interfering with healthy clotting elsewhere in the body. That’s a huge win for anyone looking to design safer biomaterials or targeted anti-thrombotic agents.
Key takeaway:
Selective peptides like P12 can block dangerous clot formation at the surface level, sparing normal clotting
Molecular targeting means less collateral impact on the broader coagulation system
Opens the door to smarter device coatings and potential therapeutic leads
Want to dive deeper into how peptides like P12 are changing the research game? Check the peptide research index for more discoveries. Researchers hunting for sourcing or suppliers can browse the vendor directory.
Peptide research continues to deliver solutions where traditional approaches stall. This is one to watch.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.